Filtered By:
Condition: Thrombosis
Drug: Activase
This page shows you your search results in order of date.
Order by Relevance | Date
Total 191 results found since Jan 2013.
Tenecteplase vs. Alteplase for Intravenous Thrombolytic Therapy of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
ConclusionsThis meta-analysis showed that tenecteplase was not inferior to alteplase in early thrombolytic therapy in patients with AIS, and was even better than alteplase on some efficacy outcomes with no significant differences in safety. However, as a result of some inherent limitations of this study, more high-quality prospective clinical studies are needed to confirm these results.
Source: Neurology and Therapy - August 8, 2023 Category: Neurology Source Type: research
O-035 Endovascular treatment of cerebral venous thrombosis involving the deep venous system
ConclusionsAlthough deep venous involvement of CVT is uncommon, these patients are at risk of quickly becoming critically ill with an elevated rate of death or dependency. Although these patients may develop stroke, hemorrhage, or neurologic decline prompting consideration of endovascular therapy, the deep cerebral venous system is not easily accessible with catheters due to small lumens and risk of perforation. It has been proposed that deep cerebral veins may have a higher chance of recanalization if venous thrombus burden is reduced in other parts of the dural venous sinuses. Current literature has not fully explored th...
Source: Journal of NeuroInterventional Surgery - July 30, 2023 Category: Neurosurgery Authors: Morel, B., Hoffman, J., Folzenlogen, Z., Roark, C., Seinfeld, J., Case, D. Tags: SNIS 20th annual meeting oral abstracts Source Type: research
Intravenous thrombolysis of ischemic stroke-Current status
Nervenarzt. 2023 May 30. doi: 10.1007/s00115-023-01500-9. Online ahead of print.ABSTRACTIntravenous thrombolysis (IVT) treatment with alteplase (rtPA) is an essential part of the routine treatment of patients with ischemic stroke since its introduction in the late 1990s. Rapid treatment is of essential importance. For patients with an unclear time window, various mismatch concepts have been established to identify salvageable brain tissue prior to IVT. Numerous official contraindications for rtPA are not evidence-based; for example, current data from observational studies show that systemic thrombolytic treatment is possib...
Source: Der Nervenarzt - May 30, 2023 Category: Neurology Authors: Peter Ringleb Gregor Bauer Jan Purrucker Source Type: research
Identification, characterization, and engineering of glycosylation in thrombolyticsa
Biotechnol Adv. 2023 May 12:108174. doi: 10.1016/j.biotechadv.2023.108174. Online ahead of print.ABSTRACTCardiovascular diseases, such as myocardial infarction, ischemic stroke, and pulmonary embolism, are the most common causes of disability and death worldwide. Blood clot hydrolysis by thrombolytic enzymes and thrombectomy are key clinical interventions. The most widely used thrombolytic enzyme is alteplase, which has been used in clinical practice since 1986. Another clinically used thrombolytic protein is tenecteplase, which has modified epitopes and engineered glycosylation sites, suggesting that carbohydrate modifica...
Source: Biotechnology Advances - May 14, 2023 Category: Biotechnology Authors: Martin Toul Veronika Slonkova Jan Mican Adam Urminsky Maria Tomkova Erik Sedlak David Bednar Jiri Damborsky Lenka Hernychova Zbynek Prokop Source Type: research
Biosimilar Tenecteplase Versus Alteplase in Acute Ischemic Stroke: A Real World Study
CONCLUSION: This present study observed no difference in the efficacy and safety between biosimilar TNK and rTPA. Our findings are in concordance with published trials showing equivalence between the two molecules.PMID:37034051 | PMC:PMC10081554 | DOI:10.4103/aian.aian_754_22
Source: Atherosclerosis - April 10, 2023 Category: Cardiology Authors: Ayush Mohan Snigdha Komakula Suhas Murali Pooja Anand Dyuti Shah V Y Vishnu Awadh Kishor Pandit Ayush Agarwal Deepti Vibha Mamta Bhushan Singh M V Padma Srivastava Rohit Bhatia Source Type: research
Effectiveness of alteplase intravenous thrombolysis combined with butylphthalide in patients with acute severe cerebral infarction
CONCLUSIONS: Alteplase intravenous thrombolysis combined with butylphthalide in the treatment of severe cerebral infarction is safe, and may significantly improve patient's neurological function and quality of life without adverse reactions.PMID:36734384 | DOI:10.5114/fn.2022.118787
Source: Folia Neuropathologica - February 3, 2023 Category: Pathology Authors: Zhengqian Wang Junshuang Che Source Type: research
